<DOC>
	<DOCNO>NCT02478424</DOCNO>
	<brief_summary>Cannabidiol ( CBD ) , non-psychotropic ingredient Cannabis sativa posse potent anti-inflammatory immunosuppressive property . In recent prospective phase II study ( NCT01385124 ) 48 consecutive adult patient undergo allogeneic hematopoietic cell transplantation give CBD 300 mg/day start 7 day transplantation day 30 , top standard GVHD prophylaxis consist cyclosporine short course methotrexate . There grade 3-4 toxicity attribute CBD . None patient develop acute GVHD consume CBD . With median follow-up 16 month , cumulative incidence rate grade 2-4 grade 3-4 acute GVHD day 100 12.1 % 5 % , respectively . Compared 101 historical control subject give standard GVHD prophylaxis , hazard ratio develop grade 2-4 acute GVHD among subject treat CBD plus standard GVHD prophylaxis 0.3 ( p=0.0002 ) . Among patient survive 100 day , cumulative incidence moderate-to-severe chronic GVHD 12 18 month 20 % 33 % , respectively . The aim study explore safety efficacy extend use CBD day 100 prevention acute chronic GVHD .</brief_summary>
	<brief_title>Extended Use Cannabidiol Prevention Graft-versus-host-disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>1 . Acute leukemia complete remission 2 . Myeloablative conditioning 3 . Matched one antigen allele mismatch sibling unrelated donor 1 . History psychosis 2 . Bronchial asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>